Biomaterials, Journal Year: 2024, Volume and Issue: 314, P. 122856 - 122856
Published: Sept. 28, 2024
Language: Английский
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Feb. 21, 2023
Abstract Lung cancer is the primary cause of mortality in United States and around globe. Therapeutic options for lung treatment include surgery, radiation therapy, chemotherapy, targeted drug therapy. Medical management often associated with development resistance leading to relapse. Immunotherapy profoundly altering approach owing its tolerable safety profile, sustained therapeutic response due immunological memory generation, effectiveness across a broad patient population. Different tumor-specific vaccination strategies are gaining ground cancer. Recent advances adoptive cell therapy (CAR T, TCR, TIL), clinical trials on cancer, hurdles discussed this review. patients (without targetable oncogenic driver alteration) reveal significant responses when treated programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade immunotherapies. Accumulating evidence indicates that loss effective anti-tumor immunity tumor evolution. vaccines combined immune inhibitors (ICI) can achieve better effects. To end, present article encompasses detailed overview recent developments immunotherapeutic landscape targeting small (SCLC) non-small (NSCLC). Additionally, review also explores implication nanomedicine immunotherapy as well combinatorial application traditional along regimens. Finally, ongoing trials, obstacles, future outlook strategy highlighted boost further research field.
Language: Английский
Citations
542
Trends in cancer, Journal Year: 2023, Volume and Issue: 9(5), P. 381 - 396
Published: Feb. 24, 2023
Language: Английский
Citations
110
Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)
Published: July 7, 2023
Abstract Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells recognize attack are isolated from patients modified tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large lymphoma, multiple myeloma by targeting CD-19 maturation Bi-specific chimeric receptors may contribute mitigating escape, but their efficacy could be limited in cases where certain cells do not express targeted Despite success cancers, technology faces challenges solid tumors, including lack of reliable antigens, hypoxic cores, immunosuppressive environments, enhanced reactive oxygen species, decreased T-cell infiltration. To overcome these challenges, current research aims identify antigens develop cost-effective, microenvironment-specific This review covers evolution against various hematological highlights faced suggests strategies obstacles, such as utilizing single-cell RNA sequencing artificial intelligence optimize clinical-grade
Language: Английский
Citations
104
Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13
Published: Dec. 14, 2022
Immunotherapy has emerged as a breakthrough strategy in cancer treatment. mRNA vaccines are an attractive and powerful immunotherapeutic platform against because of their high potency, specificity, versatility, rapid large-scale development capability, low-cost manufacturing potential, safety. Recent technological advances vaccine design delivery have accelerated vaccines’ clinical application. In this review, we present various platforms with focus on nucleic acid vaccines. We discuss rational optimization strategies for development. highlight the available lipid nanoparticles (LNPs) based systems. Finally, limitations future challenges.
Language: Английский
Citations
96
Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(5)
Published: May 1, 2024
Abstract The interplay between extracellular matrix (ECM) stiffness and the tumor microenvironment is increasingly recognized as a critical factor in cancer progression efficacy of immunotherapy. This review comprehensively discusses key factors regulating ECM remodeling, including activation cancer-associated fibroblasts accumulation crosslinking proteins. Furthermore, it provides detailed exploration how influences behaviors both immune cells. Significantly, impact on response to various immunotherapy strategies, such checkpoint blockade, adoptive cell therapy, oncolytic virus therapeutic vaccines, thoroughly examined. also addresses challenges translating research findings into clinical practice, highlighting need for more precise biomaterials that accurately mimic development novel strategies. insights offered aim guide future research, with potential enhance effectiveness modalities.
Language: Английский
Citations
79
Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)
Published: May 8, 2024
Abstract Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, exploration of emerging modalities such as immunotherapy integration medicine engineering technology therapy, efficacy these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny inhibitory milieu within GBM has underscored significance cellular constituents microenvironment their interactions with cells neurons. Novel immune targeted therapy strategies have emerged, offering promising avenues for advancing treatment. One pivotal mechanism orchestrating immunosuppression involves aggregation myeloid-derived suppressor (MDSCs), glioma-associated macrophage/microglia (GAM), regulatory T (Tregs). Among these, MDSCs, though constituting minority (4–8%) CD45 + GBM, play central component fostering evasion propelling tumor progression, angiogenesis, invasion, metastasis. MDSCs deploy intricate mechanisms that adapt dynamic (TME). Understanding interplay between provides compelling basis This review seeks elucidate inherent explore existing targets, consolidate insights into MDSC induction contribution immunosuppression. Additionally, comprehensively surveys ongoing clinical trials potential strategies, envisioning future where targeting could reshape landscape GBM. Through synergistic other modalities, this approach can establish multidisciplinary, multi-target paradigm, ultimately improving prognosis quality life patients
Language: Английский
Citations
66
ACS Infectious Diseases, Journal Year: 2023, Volume and Issue: 9(7), P. 1283 - 1302
Published: June 22, 2023
The emergence of antibiotic-resistant bacterial strains is a source public health concern across the globe. As discovery new conventional antibiotics has stalled significantly over past decade, there an urgency to develop novel approaches address drug resistance in infectious diseases. use CRISPR-Cas-based system for precise elimination targeted populations holds promise as innovative approach antimicrobial agent design. CRISPR-Cas targeting celebrated its high versatility and specificity, offering excellent opportunity fight antibiotic pathogens by selectively inactivating genes involved resistance, biofilm formation, pathogenicity, virulence, or viability. strategy can enact effects two approaches: inactivation chromosomal curing plasmids encoding resistance. In this Review, we provide overview main systems utilized creation these antimicrobials, well highlighting promising studies field. We also offer detailed discussion about most commonly used mechanisms delivery: bacteriophages, nanoparticles, conjugative plasmids. Lastly, possible interference that should be considered during intelligent design approaches.
Language: Английский
Citations
62
Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 367, P. 737 - 767
Published: Feb. 14, 2024
Language: Английский
Citations
25
Viruses, Journal Year: 2022, Volume and Issue: 14(2), P. 278 - 278
Published: Jan. 28, 2022
The human body is colonized by a wide range of microorganisms. field viromics has expanded since the first reports on detection viruses via metagenomic sequencing in 2002. With continued development reference materials and databases, viral approaches have been used to explore known components virome discover new from various types samples. attracted substantial interest outbreak coronavirus disease 2019 (COVID-19) pandemic. Increasing numbers studies review articles documented diverse sites body, as well interactions between host with regard health disease. However, there few direct causal relationships. Viral analyses often lack standard references are potentially subject bias. Moreover, most virome-related focused gut did not investigate roles other This presents an overview metagenomics, updates regarding relations alterations pathogenesis diseases, recent findings related COVID-19, therapeutic applications virome.
Language: Английский
Citations
66
Pharmacological Research, Journal Year: 2023, Volume and Issue: 189, P. 106701 - 106701
Published: Feb. 14, 2023
Chimeric antigen receptor T-cell (CAR-T) is particularly prominent in hematological but not solid tumors, mainly based on the complex tumor immune microenvironment. Oncolytic virus (OVs) an emerging adjuvant therapy method. OVs may prime lesions to induce anti-tumor response, thereby enhancing CAR-T cells functionality and possibly increasing response rates. Here, we combined targeting carbonic anhydrase 9 (CA9) oncolytic adenovirus (OAV) carrying chemokine (C-C motif) ligand 5 (CCL5), cytokine interleukin-12 (IL12) explore effects of this combination strategy. The data showed that Ad5-ZD55-hCCL5-hIL12 could infect replicate renal cancer cell lines induced a moderate inhibition xenografted nude mice. IL12 mediated by promoted phosphorylation Stat4 cells, secrete more IFN-γ. We also found Ad5-ZD55-hCCL5-hIL-12 with CA9-CAR-T significantly increased infiltration mass, prolonged survival mice restrained growth immunodeficient Ad5-ZD55-mCCL5-mIL-12 increase CD45+CD3+T prolong immunocompetent These results provided feasibility for which demonstrated sufficient potential prospects treatment tumors.
Language: Английский
Citations
30